Combination therapy when metformin is not an option for type 2 diabetes

The Annals of Pharmacotherapy
Jennifer D Goldman-Levine

Abstract

Consensus on combination options for patients with type 2 diabetes mellitus (T2DM) unable to use metformin is lacking. This review summarizes data describing-non-metformin based combination therapy. PubMed searches (January 1990 to August 2014) were conducted with terms for newer drug therapies alone and with the term combination; filters were applied for Clinical Trial, Meta Analysis, and English language. Results were reviewed for multicenter, randomized controlled trials of non-metformin-based combination therapy conducted in the past 5 years and specific to the US or multinational populations. Although multiple injectable and oral agents have been studied in combination with metformin for management of T2DM, data are more limited for combinations without metformin. Combinations of incretins (injectable glucagon-like peptide-1 receptor agonists or oral dipeptidyl peptidase-4 [DPP-4] inhibitors) with a sulfonylurea, thiazolidinedione, or insulin are well studied and provide greater glucose-lowering efficacy than monotherapy. Incretins are associated with a low risk of hypoglycemia when used as monotherapy; the dosage of sulfonylurea or insulin should be reduced when used in combination. Newer studies are investigating the com...Continue Reading

References

Feb 1, 1993·Annals of Internal Medicine·S StenmanL C Groop
Oct 27, 2004·Diabetes Care·John B BuseUNKNOWN Exenatide-113 Clinical Study Group
Dec 28, 2007·Diabetes Research and Clinical Practice·Jochen Seufert, Richard Urquhart
Jun 12, 2009·Nutrition, Metabolism, and Cardiovascular Diseases : NMCD·M MonamiE Mannucci
Oct 30, 2009·The Journal of Clinical Endocrinology and Metabolism·Priscilla HollanderUNKNOWN CV181-013 Investigators
Dec 18, 2009·Metabolism: Clinical and Experimental·Giuseppe DerosaArrigo F G Cicero
Mar 20, 2010·Current Medical Research and Opinion·Angel RodríguezJesús Reviriego
Apr 15, 2010·JAMA : the Journal of the American Medical Association·Olivia J PhungCraig I Coleman
Apr 27, 2010·Diabetes, Obesity & Metabolism·Vivian A FonsecaBart Staels
Oct 28, 2010·The Annals of Pharmacotherapy·Jessica L KerrKatherine A Petkewicz
Jan 5, 2011·Toxicon : Official Journal of the International Society on Toxinology·Brian L Furman
Jan 6, 2011·Patient Preference and Adherence·Marco Dacosta DibonaventuraLarry Radican
May 13, 2011·Diabetes & Vascular Disease Research : Official Journal of the International Society of Diabetes and Vascular Disease·Priscilla L HollanderUNKNOWN CV181013 Investigators
May 13, 2011·Diabetes & Vascular Disease Research : Official Journal of the International Society of Diabetes and Vascular Disease·Antonio R ChacraUNKNOWN CV181040 Investigators
May 28, 2011·Diabetes Care·Kasia J LipskaSilvio E Inzucchi
Jan 5, 2012·Advances in Therapy·Matteo MonamiEdoardo Mannucci
Mar 3, 2012·Diabetes & Vascular Disease Research : Official Journal of the International Society of Diabetes and Vascular Disease·Celine FooteBruce Neal
Nov 29, 2012·Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists·Aaron I VinikJ Michael Gaziano
Apr 20, 2013·Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists·Alan J GarberUNKNOWN American Association of Clinical Endocrinologists
Jun 12, 2013·Postgraduate Medicine·Agata PtaszynskaJames List

❮ Previous
Next ❯

Citations

Dec 18, 2016·Diabetes, Obesity & Metabolism·Fabrice Bonnet, André Scheen
Mar 21, 2017·Annals of Global Health·Virginia RowthornJohn Zervos

❮ Previous
Next ❯

Clinical Trials Mentioned

NCT02152371

Software Mentioned

CANVAS

Related Concepts

Related Feeds

Cardiovascular Biology of GLP-1

Glucagon-like peptide 1 (GLP-1) plays a role in glucose metabolism, energy homeostasis, and inflammation suppression. GLP-1 receptor signaling has been shown to impact cardiovascular function. This feed focuses on the role of GLP-1 and GLP-1 receptor agonists on cardiovascular biology.

Biomarkers for Type 2 Diabetes

Biomarkers can help understand chronic diseases and assist in risk prediction for prevention and early detection of diseases. Here is the latest research on biomarkers in type 2 diabetes, a disease in which the body is unable to produce or properly use insulin.

CV Disorders & Type 2 Diabetes

This feed focuses on the association of cardiovascular diseases in patients with type 2 diabetes.